3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
1
SCLC,Extensive Stage
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metastatic Castration-sensitive Prostate Cancer
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
6
Gemcitabine
5
Oxaliplatin
3
Irinotecan
3
durvalumab
2
Folfox protocol
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
trastuzumab deruxtecan
1
toripalimab
1
pembrolizumab
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
fludarabine
1
envafolimab
1
encorafenib
1
brigimadlin
1
binimetinib
1
Trastuzumab
1
Pemetrexed
1
Nivolumab
1
Leucovorin
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
niraparib
×
30 days
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled